Activity Provided By:

ACHL

Deciphering Rare irAEs: A Go-to-Guide

Overview / Abstract:	This immersive CME infographic will provide a stepwise visual to support improved recognition and management of rare immune-related adverse events (irAEs) for patients on immune checkpoint inhibitors (ICPIs). The infographic will synthesize and visualize data, guidelines and decision-making recommendations, as well as imbed faculty commentaries that offer “how-to” methods for introducing strategies and practical resources that support personalized therapeutic management. This activity is intended for oncologists, hematologists, gastroenterologists, cardiologists, internists, emergency medicine physicians and other specialists who care for oncology patients receiving immune checkpoint inhibitors. Upon completion of this activity, participants will be able to: - Differentiate irAEs in patients receiving immune checkpoint inhibitor therapy from those associated with traditional treatment modalities - Outline the occurrence, identification and management of rare irAEs - Discuss strategies including recent guideline recommendations for monitoring and managing irAEs - Integrate management of irAEs into the overall treatment of patients with cancer and improve communication between patients and their care team
Expiration	Jul 10, 2021
Discipline(s)	Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME, Radiology / RAD Tech CE, Respiratory Therapy CE
Format	Online, Webinar / Webcast / Video
Credits / Hours	1.0
Accreditation	ACCME, CBRN
Presenters / Authors / Faculty	John A. Thompson, MD Medical Director, Phase I Clinical Trials Program Seattle Cancer Care Alliance Professor, Division of Oncology University of Washington School of Medicine Marianne Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP Assistant Professor of Nursing Yale University School of Nursing
Activity Specialities / Related Topics	Adverse Drug Reactions / ADR, Cardiology / Cardiovascular, Education / Teaching, Emergency Medicine, Endocrinology, Hematology, Immunology / Immunosuppression, Neurology, Oncology / Cancer / Radiation Therapy, Pulmonary Medicine / COPD
Sponsors / Supporters / Grant Providers	Supported by an educational grant from Bristol Myers Squibb.
Keywords / Search Terms	ACHL Immune checkpoint inhibitors, ICPIs, adverse events, anti–CTLA-4, ipilimumab, YERVOY, anti PD-1 antibody, nivolumab, OPDIVO, pembrolizumab, anti-PD-L1 antibody, atezolizumab, durvalumab, avelumab, pneumonitis, myocarditis, BMS, CME, infographic, Brahmer, Davies, medical education, ASCO, NCCN, EULAR, oncology, hematology, irAEs, irAE, AEs, IO agents, immunooncology, rare irAEs Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map